Neumora Therapeutics Announces Positive Phase 1b Results for NMRA‑511 in Alzheimer’s Disease Agitation

Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical‑stage biopharmaceutical company, announced on January 5, 2026, positive results from its Phase 1b signal‑seeking study evaluating NMRA‑511 in people with agitation associated with Alzheimer’s disease (AD). NMRA‑511 is an oral, highly potent, brain‑penetrant, selective antagonist of the vasopressin 1a receptor (V1aR) designed to target agitation and related symptoms in AD. In the study, NMRA‑511 achieved a 15.7‑point reduction on the mean Cohen‑Mansfield Agitation Inventory (CMAI) total score, indicating a clinically meaningful effect on agitation symptoms. The compound showed an especially strong effect size in a pre‑specified subgroup of patients with elevated anxiety and demonstrated a favorable safety and tolerability profile with no reports of somnolence or sedation. The Phase 1b study included healthy elderly adults and patients with AD‑related agitation in a randomized, double‑blind, placebo‑controlled design. In the modified analysis set of 71 patients, NMRA‑511 showed consistent improvements over placebo at Weeks 6 and 8. Among the 36 patients with higher baseline anxiety, placebo‑adjusted changes in CMAI scores were larger, suggesting greater benefit in this subgroup. Treatment‑emergent adverse events were generally mild to moderate, and discontinuation due to adverse events was low (2.5 %). Neumora plans to advance NMRA‑511 into further development, including initiating a multiple ascending‑dose extension study in 2026, exploring extended‑release formulation for once‑daily dosing, and progressing to a Phase 2/3 dose‑ranging trial. The company also hosted a conference call to discuss the results and future plans. #AlzheimersResearch #BiotechNews #NMRA511 #NeumoraTherapeutics #SlimScan #GrowthStocks #CANSLIM